Service de Physiologie d'Explorations Fonctionnelles, Faculty of Medicine Paris Ile-de-France Ouest, University of Versailles-Saint Quentin, Garches, France. roche.nicolas@rpc.aphp.fr
OBJECTIVES: To study the incidence of clinical signs linked to botulinum toxin type A (BoNTA) spread from the injection site.
METHODS: Single-center, retrospective, cohort study. All patients who received BoNTA injections for spasticity treatment were assessed 1 month postinjection. Adverse effects indicative of BoNTA treatment were systematically sought. Any patient with adverse effects possibly due to BoNTA spread underwent further clinical examination and single-fiber electromyography. One patient underwent neuromuscular biopsy.
RESULTS: Between January and September 2005, 266 BoNTA injection sessions (187 patients) were performed (233 BOTOX, 33 Dysport). Five patients presented with clinical signs of toxin spread. Four of these underwent single-fiber electromyography, which showed increased jitter. Neuromuscular biopsy detected signs of recent denervation without signs of reinnervation.
CONCLUSIONS: Diffusion diagnosis of BoNTA from the injection site depends on clinical, temporal, and electromyographic factors. Clinical expression of spread varies widely, with mechanisms remaining largely unknown, and further prospective, randomized clinical trials are required.